Virtus ETF Advisers’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Virtus ETF Advisers’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-52,472	Closed	-$220K	–	494
2023 Q1	$220K	Buy	52,472 +930	+2%	+$4.83K	0.12%	300
2022 Q4	$310K	Buy	51,542 +8,172	+19%	+$44.6K	0.16%	250
2022 Q3	$252K	Buy	43,370 +635	+1%	+$3.96K	0.1%	288
2022 Q2	$255K	Buy	+42,735	New	+$219K	0.09%	293

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Virtus ETF Advisers's CTIC Position: Q2 2023 in Review

Virtus ETF Advisers sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 52,472 shares — an estimated $220K sold.

Virtus ETF Advisers first reported a position in CTIC in Q2 2022 and held it in 4 quarters. The position peaked at $310K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Virtus ETF Advisers reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Virtus ETF Advisers sold 52,472 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $220K.
Virtus ETF Advisers first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 4 quarters.
Virtus ETF Advisers's CTI BioPharma Corp. (DE) Common Stock position peaked at $310K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.